# VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

> **NCT04842747** · PHASE3 · COMPLETED · sponsor: **Veru Inc.** · enrollment: 204 (actual)

## Conditions studied

- SARS-CoV Infection

## Interventions

- **DRUG:** VERU-111

## Key facts

- **NCT ID:** NCT04842747
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-18
- **Primary completion:** 2022-07-06
- **Final completion:** 2022-07-06
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842747, "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04842747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*